Case Report

**Composite t(14;18)-Negative Follicular Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma**

**John Patrick O’Neill**,1 Fiona Quinn,1 Anita Dowling,1 Jan Walker,1 Triona Hayes,2 Brian Bird,2 and Richard Flavin1

1St. James’s Hospital, Dublin, Ireland
2Bons Secours Hospital, Cork, Ireland

Correspondence should be addressed to John Patrick O’Neill; oneilljp@tcd.ie

Received 7 February 2018; Revised 5 July 2018; Accepted 15 July 2018; Published 2 August 2018

1.Introduction

Composite lymphomas (CLs) are defined by the rare simultaneous occurrence of two or more distinct lymphomas within one tissue or organ and were first described as an entity in 1954 [1]. It is estimated that CL accounts for approximately 1–4% of all lymphoma diagnoses [2]. CL has been typically found to comprise a classical Hodgkin lymphoma (cHL) and a non-Hodgkin lymphoma (NHL) such as follicular lymphoma (FL) [3], chronic lymphocytic leukaemia (CLL) [4], mantle cell lymphoma (ML) [5], or diffuse large B-cell lymphoma (DLBCL) [6]. Combinations of two NHL subtypes have also been described [7].

A rare occurrence is that of a CL including nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Herein, we describe a case of composite FL and NLPHL diagnosed concurrently within the same lymph node.

2. Clinical History

A 51-year-old man with a background history of lower limb rash and unexplained fatigue had an incidental finding of bulky abdominopelvic lymphadenopathy during investigation for prostatitis. Skin punch biopsy of the flank and medial left calf noted features of papular urticaria in both specimens. In addition, the left calf biopsy showed features of a mixed septal and lobular panniculitis. Retroperitoneal lymph node core biopsy and open intra-abdominal nodal biopsy at minilaparotomy in another institution failed to yield sufficiently the diagnostic material, and a PET-directed laparoscopic left iliac lymph node excisional biopsy was performed. Following diagnosis, he was treated with bendamustine and rituximab with a complete metabolic response. He has completed 1 of 2-year maintenance rituximab with no clinical evidence of relapse.

3. Pathological Findings

Haematoxylin and eosin (H&E) staining of the lymph node showed one discrete block of the biopsy nodular areas composed of small lymphocytes, epithelioid histiocytes, immunoblasts, and lymphocyte-predominant (LP) cells (Figure 1). There was background progressive transformation of germinal centres (PTGC). The LP cells were...
positive for immunohistochemical stains CD45, CD20, CD79a, PAX-5, OCT-2, BOB-1, BCL-6, EMA, and MUM-1 and were negative for CD30 and CD15. The background T-cell population was CD4 predominant without aberrant T-cell antigen loss (CD2, CD5, and CD7 positive). PD-1-positive T-cell rosettes were seen around LP cells [8]. The follicular dendritic meshwork was highlighted by CD21 and CD23 staining. EBV-encoded small RNAs in situ hybridization (EBER-ISH) was negative. Overall, the above morphology and immunoprofile were felt to be in keeping with NLPHL. Multiplex polymerase chain reaction (PCR) analysis was performed on a whole discrete section of NLPHL, and a polyclonal immunoglobulin (Ig) gene rearrangement profile was detected. In addition, the t(14;18) BCL2-JH translocation was not detected. Insufficient material was available for FISH analysis and for laser capture microdissection for downstream PCR analysis.

In a separate block section of the same lymph node biopsy, there were neoplastic follicles present containing centroblasts (numbering >15 per high-power field) and admixed centrocytes (Figure 2). Immunohistochemistry showed that the neoplastic follicles were positive for CD20, CD79a, CD10, BCL-6, and BCL-2 (weak) with equivocal staining for MUM-1. The Ki-67 proliferation index within follicles was 50%. The morphology and immunoprofile were in keeping with a follicular lymphoma (FL), grade 3a, follicular pattern. Multiplex PCR performed on FFPE tissue from a distinct area of FL detected a clonal Ig light-chain kappa (V/JC intron-kde) gene rearrangement. Multiplex PCR did not detect a t(14;18) BCL2-JH translocation. Fluorescence in situ hybridization (FISH) did not detect either the t(14;18)(q32;q21) translocation or a BCL-2 rearrangement (Figure 3).

4. Materials and Methods

The lymph node was fixed in 10% neutral-buffered formalin followed by paraffin embedding. Immunohistochemistry and in situ hybridization were performed routinely following standardized protocols. Antibodies used were CD3, CD4, CD5, CD7, CD8, CD10, CD15, CD20, CD23, CD30, EMA, Ki-67, Pax-5, and Bcl-2 (Ventana); CD21, CD79a, MUM-1, Bcl-6, and PD-1 (Cell Marque); and Oct-2 and Bob-1 (Leica). EBV-encoded small RNAs in situ hybridization (EBER-ISH) was performed on FFPE sections using the fluorescein-conjugated PNA probe (Roche). Fluorescence in situ hybridization analyses for t(14;18) and BCL-2 rearrangements were performed on FFPE samples according to standardized protocols using probe sets LSI IGH/BCL2 t(14;18)(q32;q21) and LSI BCL2 (dual colour) (Abbott Vysis Inc, Downers Grove, IL). t(14;18)(q32;q21) and LSI BCL2 were deemed positive if >10% of nonoverlapped lymphoma nuclei had a demonstrable translocation or break-apart signals, respectively. DNA was extracted from FFPE using Qiagen DNASe kits. Multiplex polymerase chain reaction (PCR) analysis was performed using BioMED primers and...
probes with PCR products visualized using GeneScan as previously described [9]. Extracted DNA from FFPE was also tested for the presence of the t(14;18) BCL2-JH translocation using multiplex PCR.

**Figure 2:** Follicular lymphoma. (a) H&E staining, low power, showing pronounced nodular effacement by closely packed nodules lacking mantle zones. (b) H&E staining, high power, showing neoplastic follicle containing centroblasts (>15 per HPF). Immunostaining for (c) CD20 and (d) CD10 showing follicle positivity.

5. Discussion

This report outlines a second documented case of a composite lymphoma comprising NLPHL and FL. In the previously published case of composite NLPHL and FL, the t(14;18) translocation was detected by FISH, but interestingly, no clonal immunoglobulin gene rearrangements were detected in the FL component, which is in direct contrast to our case.

Cases of composite cHL and FL have been previously described [10–12]. In two of these cases, the cHL and FL components were shown to be clonally related, with shared and distinct Ig V mutations in each instance [10, 11]. This suggests a common origin of the cHL and FL components. Indeed, in an extended series of 19 composite cases involving cHL and other non-Hodgkin lymphomas, where clonality was examined, shared clonality was demonstrated in 12/19 (63%) cases [13]. Furthermore, in four composite cases involving NLPHL, shared clonality has been shown in cases involving DLBCL [14], T-cell-rich large B-cell lymphoma [15], and cHL [16, 17]. The common finding of shared clonality in cases described as composite lymphomas raises the question of whether these lymphomas are in fact “distinct” entities by Custer’s 1954 definition [1, 18]. Composite lymphomas where common clonality is present may just represent differing phenotypes of an identical progenitor clone. In our case, we were unable to determine whether shared clonality was present due to insufficient tissue available for laser capture microdissection. In the single

**Figure 3:** Fluorescence in situ hybridization photomicrograph of the follicular lymphoma component using LSI IGH/BCL2 t(14;18) (q32;q21) dual colour probes showing no evidence of t(14;18) translocation in nonoverlapped nuclei.
other reported instance of composite NLPHL and FL, the authors were also unable to determine the clonal relationship [19].

Finally, composite lymphomas may be more common than previously thought. A 2015 Japanese study examined 154 cHL cases and found a 20% incidence of composite lymphoma in patients ≥40 years [12]. Interestingly, they also noted that marrow involvement by the cHL component and the presence of a high-grade component were adverse prognostic factors.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] R. Custer, “Pitfalls in the diagnosis of lymphoma and leukemia from the pathologist’s point of view,” in Proceedings of Second National Cancer Conference, pp. 554–557, New York City, NY, USA, 1954.

[2] S. Thirumala, M. Esposito, and A. Fuchs, “An unusual variant of composite lymphoma: a short case report and review of the literature,” Archives of Pathology and Laboratory Medicine, vol. 124, no. 9, pp. 1376–1378, 2000.

[3] T. Marafioti, M. Hummel, I. Anagnostopoulos et al., “Classical Hodgkin’s disease and follicular lymphoma originating from the same germinal center B cell,” Journal of Clinical Oncology, vol. 17, no. 12, pp. 3804–3809, 1999.

[4] L. de Leval, M. Vivario, B. De Prijck et al., “Distinct clonal origin in two cases of Hodgkin’s lymphoma variant of Richter’s syndrome associated with EBV infection,” American Journal of Surgical Pathology, vol. 28, no. 5, pp. 679–686, 2004.

[5] A. Caleo, A. Sánchez-Aguilera, S. Rodriguez et al., “Composite Hodgkin lymphoma and mantle cell lymphoma: two clonally unrelated tumors,” American Journal of Surgical Pathology, vol. 27, no. 12, pp. 1577–1580, 2003.

[6] R. K. Thomas, C. Wickenhauser, D. Kube et al., “Repeated clonal relapses in classical Hodgkin’s lymphoma and the occurrence of a clonally unrelated diffuse large B-cell non-Hodgkin lymphoma in the same patient,” Leukemia and Lymphoma, vol. 45, no. 5, pp. 1065–1069, 2004.

[7] D. F. Boyer, N. I. Lindeman, N. L. Harris, and J. A. Ferry, “Peripheral T-cell lymphomas with cytotoxic phenotype in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma,” American Journal of Surgical Pathology, vol. 38, no. 2, pp. 279–288, 2014.

[8] S. H. Nam-Cha, G. Roncador, M. A. Piris et al., “PD-1 a follicular T-cell marker useful for recognising nodular lymphocyte predominant Hodgkin lymphoma,” American Journal of Surgical Pathology, vol. 32, no. 8, pp. 1252–1257, 2008.

[9] J. J. Van Dongen, A. W. Langerak, M. Brüggemann et al., “Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936,” Leukemia, vol. 17, no. 12, pp. 2257–2317, 2003.

[10] A. Bräutinger, M. L. Hansmann, J. G. Strickler et al., “Identification of common germinal-center B-cell precursors in two patients with both Hodgkin’s disease and non-Hodgkin’s lymphoma,” New England Journal of Medicine, vol. 340, no. 16, pp. 1239–1247, 1999.

[11] R. Küppers, A. B. Sousa, A. S. Baur, J. G. Strickler, K. Rajewsky, and M. L. Hansmann, “Common germinal-center B-cell origin of the malignant cells in two composite lymphomas, involving classical Hodgkin’s disease and either follicular lymphoma or B-CLL,” Molecular Medicine, vol. 7, no. 5, pp. 285–292, 2001.

[12] A. M. Maeshima, H. Taniguchi, J. Nomoto et al., “Clinico-pathological features of classical Hodgkin lymphoma in patients ≥40 years old, with special reference to composite cases,” Japanese Journal of Clinical Oncology, vol. 45, no. 10, pp. 921–928, 2015.

[13] R. Küppers, U. Dürrsen, and M. L. Hansmann, “Pathogenesis, diagnosis, and treatment of composite lymphomas,” Lancet Oncology, vol. 15, no. 10, pp. e435–e446, 2014.

[14] T. Ohno, J. Z. Huang, G. Wu, K. H. Park, D. W. Weisenburger, and W. C. Chan, “The tumor cells in nodular lymphocyte-predominant Hodgkin disease are clonally related to the large cell lymphoma occurring in the same individual. Direct demonstration by single cell analysis,” American Journal of Clinical Pathology, vol. 116, no. 4, pp. 506–511, 2001.

[15] S. Shimodaira, E. Hidaka, and T. Katsuyama, “Clonal identity of nodular lymphocyte-predominant Hodgkin’s disease and T-cell-rich B-cell lymphoma,” New England Journal of Medicine, vol. 343, no. 15, pp. 1124–1125, 2000.

[16] J. Y. Song, F. C. Eberle, L. Xi et al., “Coexisting and clonally identical classic Hodgkin lymphoma and nodular lymphocyte predominant Hodgkin lymphoma,” American Journal of Surgical Pathology, vol. 35, no. 5, pp. 767–772, 2011.

[17] M. Szczepanowski, N. Masqué-Soler, I. Oschlies et al., “Composite lymphoma of nodular lymphocyte-predominant and classical Hodgkin lymphoma-Epstein-Barr virus association suggests divergent pathogenesis despite clonal relatedness,” Human Pathology, vol. 44, no. 7, pp. 1434–1439, 2013.

[18] M. Steinhoff, M. Hummel, C. Assaf et al., “Cutaneous T cell lymphoma and classic Hodgkin lymphoma of the B cell type within a single lymph node: composite lymphoma,” Journal of Clinical Pathology, vol. 57, no. 3, pp. 329–331, 2004.

[19] J. L. Dargent, L. Lespagnard, I. Meiers, C. Bradstreet, and W. C. Chan, “The tumor cells in nodular lymphocyte-predominant and classical Hodgkin lymphoma-originating from the pathologist’s point of view,” in Proceedings of Second National Cancer Conference, pp. 554–557, New York City, NY, USA, 1954.